Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-O19
- Development stage
- Preclinical
- Lead developer
- Oncurie
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
64Cu-O19 is a preclinical-stage copper-64 (64Cu) radiolabeled porphyrin-folate conjugate designed for positron emission tomography (PET) imaging of folate receptor alpha (FRα)-overexpressing cancers, particularly ovarian cancer. Developed by Oncurie in collaboration with North Carolina State University and the University of Alabama at Birmingham, the compound consists of a folate targeting motif conjugated to a proprietary porphyrin chelator core that binds copper-64 with high affinity. The O19 compound features a compact swallowtail-like structure and is conjugated at either the alpha- or gamma-carboxylic acid site of folic acid. In preclinical models of ovarian cancer, 64Cu-O19 has demonstrated high uptake in FRα-positive cells and favorable biodistribution, making it a promising diagnostic candidate in a theranostic pair alongside a copper-67 therapeutic counterpart.
- Other names
- [64Cu]Cu-O19copper-64 labeled O19copper64 labeled O19copper 64 labeled O19
02
Targets
FOLR1 (FRα)
Beyond the preview
Go deeper on 64Cu-O19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-O19.